Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848852 | 0.86 | GAA (0.45) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL11257446 | 0.83 | ALDH1A1 (0.42) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL21615521 | 0.81 | ALDH1A1 (0.48) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL374322 | 0.80 | GAA (0.43) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL12139476 | 0.79 | ALDH1A1 (0.44) | ALDH1A1NPC1GAAMAPTNPSR1 | |
| SCHEMBL6777378 | 0.78 | TUBB4A (0.45) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL24636823 | 0.77 | HTR2A (0.43) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL2656026 | 0.77 | ALDH1A1 (0.50) | ALDH1A1GAACYP3A4MAPTNPSR1 | |
| SCHEMBL30763265 | 0.77 | POLB (0.52) | ALDH1A1NPC1GAACYP3A4MAPT | |
| SCHEMBL8034927 | 0.77 | POLB (0.52) | ALDH1A1NPC1GAACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| CN-120020135-A | Pyrimidinone derivative and application thereof in medicine | 康百达（四川）生物医药科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| WO-2024249817-A1 | TRICYCLIC PKMYT1 KINASE INHIBITORS | ENLIVEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| CN-117729920-A | Carboxamide pyrrolopyrazines and pyridine compounds useful as MYT1 inhibitors and their use in the treatment of cancer | 修复治疗公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4319752-A1 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | Repare Therapeutics Inc. (CA) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022213204-A9 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022213204-A9 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | WO | disclosed |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2023-05-25 | — | — | US | disclosed |
| WO-2022213204-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-10-13 | — | — | WO | disclosed |
| WO-2021195781-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195782-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195782-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195781-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| US-6750349-B2 | SUPERIOR GASTROKINETIC PROPERTIES | JANSSEN PHARMACEUTICS, N.V. (BE) | 2004-06-15 | — | — | US | disclosed |
| EP-1000028-B1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-04-24 | — | — | US | disclosed |
| EP-1000028-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002494-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, ALK, CBR1 | ALDH1A1 2457/4885NPC1 1191/4885GAA 350/4885 |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | MYT1, MNAT1, MYLK3 | ALDH1A1 4237/4885NPC1 2616/4885GAA 3326/4885 |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | PLK1, CSNK1A1, CSNK1G1 | ALDH1A1 4093/4885NPC1 995/4885GAA 1717/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | ALDH1A1 1899/4885NPC1 4501/4885GAA 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.